Exhibit 99.1 Three upcoming posters, including an update from ongoing Phase 1 trial of Calidi's CLD-101 program, to be presented at 2024 ASCO Annual Meeting Unveiled RTNova systemic platform allowing for ease of administration and ability to target multiple tumor types SAN DIEGO—(BUSINESS WIRE)— Calidi Biotherapeutics Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today reported its first quarter 2024 operating and financi ...